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Predictive Models of Toxicity With
External Radiotherapy for Prostate
Cancer
Clinical Issues*
Riccardo Valdagni, MD, PhD1; Tiziana Rancati, PhD1; and Claudio Fiorino, PhD2
The objective of the current study was to analyze the state of the art and present limitations of available
predictive clinical models (when available) estimating the risk of genitourinary tract and small bowel com-
plications, erectile dysfunction, and acute and late symptoms of the rectal syndrome caused by prostate
cancer external irradiation. An analysis of the literature indicated that very limited attention has been
devoted to the development of ‘‘integrated,’’ patient-tailored, user-friendly, and clinically usable tools for
the prediction of external beam radiotoxicity. In this article, the authors reported on the multivariate corre-
lation between late genitourinary and gastrointestinal toxicities and clinical/dosimetric risk factors, as
well as on the first set of nomograms developed to predict acute and late rectal side effects. At the pres-
ent state of knowledge, the use of nomograms as predictive instruments of radiotoxicity appears to be
particularly attractive for several main reasons. They are ‘‘user friendly’’ and easily developed using the
results of multivariate analyses, as they weigh the combined effects of multiple independent factors
found to be correlated with the selected clinical endpoint. The integrated evaluation of clinical and dosi-
metric parameters in the single patient can help to provide a tailored probability of the specific outcome
considered. Predicting a high probability of toxicity could avoid unnecessary daily costs for the individual
patient in terms of quality of life modification during and after treatment, helping patients in the deci-
sion-making process of choosing the best individual, quality of life–related treatment, and clinicians in
better tailoring the treatment to patient’s characteristics. Cancer 2009;115(13 suppl):3141–3149. VC 2009
American Cancer Society.
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In the recent years, there has been growing interest among radiation oncologists in developing predictive
models of practical utility (ie, probability formulas and nomograms) in prostate cancer irradiation. Nearly
all have been focused on disease control prediction (to help physicians and to counsel patients in the deci-
sion-making process),1-5 on the prediction of pathologic extension (to select anatomic target[s] for external
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beam radiation therapy [EBRT]6-8), on supporting radia-
tion oncologists in the decision of dose levels to be deliv-
ered,9 and on helping clinicians choose the appropriate
combination of therapies both in standard practice (ie,
neoadjuvant/adjuvant androgen suppression)3,10 and in
experimental clinical trials (ie, chemotherapy for high-risk
patients11 as in the Radiation Therapy Oncology Group
[RTOG] 0521 study and in the Dana-Farber Cancer
Institute Protocol 05-043).
Curiously, very limited attention and inadequate
efforts have been devoted to the development of ‘‘easy to
use’’ tools for the prediction of probability of radiation
side effects in the individual patient.
Predicting radiation morbidity is of great impor-
tance because it can prevent unnecessary worsening of
quality of life for the individual patient, and can help in
introducing planning corrections to better personalize
radiation treatments.
The objective of the current study was to analyze the
state of the art and present limitations of available clini-
cally usable models predicting the risk of genitourinary
(GU) tract and bowel complications, of erectile dysfunc-
tion, and of acute and late symptoms of the rectal syn-
drome (lower gastrointestinal [LGI]) caused by prostate
cancer external irradiation.
GU Complications
Few studies exist in the literature clarifying the role of
clinical-dosimetric variables affecting the risk of develop-
ing symptoms and signs of the GU syndrome; no user-
friendly predictive tool is currently available to assist clini-
cians in the prediction and minimization of such radiation
sequelae. Furthermore, information regarding clinical var-
iables potentially affecting GU toxicity is lacking, with
only limited data on dosimetric factors being known.12,13
Results on factors involved in conditioning GU morbid-
ities are still controversial, as can easily be deduced from 3
recently reported large analyses. Peeters et al (multicenter
Dutch randomized trial)14 found prior transurethral
resection of prostate, androgen deprivation therapy, and
pretreatment GU symptoms (but no dose influence) all
statistically related to late RTOG/European Organization
for Research and Treatment of Cancer (EORTC) urinary
toxicity, whereas Zelefsky et al (Memorial Sloan Kettering
Cancer Center [MSKCC] Group 3-dimensional confor-
mal radiation therapy [3DCRT] þ intensity-modulated
radiation therapy [IMRT] patients)15 found radiation
dose (<81 grays [Gy] vs>81Gy) and acute toxicity (grade
0-1 vs 2-4) to be the only variables significantly condition-
ing late GU morbidity. Cahlon et al (MSKCC Group
IMRT patients)16 found GU medications before IMRT
and age >70 years to be significantly correlated with the
presence of grade 2 late morbidity. Table 1 summarizes
the major findings (on late GU toxicity) from selected
studies.
These difficulties, most likely also related both to
the maintaining of similar bladder filling within the same
study and to different instructions for bladder filling
among different studies, clearly explain why prediction
tools are lacking; only 1 model exploiting artificial neural
networks (ANNs)17 has been published to date, which
partially and theoretically addressed the issue of predic-
tion of radiation-induced bladder toxicity. Specifically,
Table 1. Clinical Factors Found to Be Correlated With Late Genitourinary Toxicity (Organ: Bladder;








Peeters 200514 669 Prior TURP Yes vs no 1.7 <.01 RTOG/EORTC grade 2
Peeters 200514 669 Prior TURP Yes vs no 3.1 <.01 RTOG/EORTC grade 3
Peeters 200514 669 Androgen deprivation Yes vs no 2.2 <.01 RTOG/EORTC grade 2
Peeters 200514 669 Androgen deprivation Yes vs no 2.3 .03 RTOG/EORTC grade 3
Peeters 200514 669 Pretreatment GU symptoms Grade 2 vs grade <2 2.2 <.01 RTOG/EORTC grade 2
Zelefsky 200815 1571 Acute toxicity Grade 2 vs grade <2 3.2 <.01 CTCAE grade 2
Cahlon 200816 478 Pre-RT GU medication Yes vs no <.01 CTCAE grade 2
Cahlon 200816 478 Age <70 y vs 70 y <.01 CTCAE grade 2
TURP indicates transurethral resection of the prostate; RTOG, Radiation Therapy Oncology Group; EORTC, European Organization for Research and Treat-
ment of Cancer; GU, genitourinary; CTCAE, Common Terminology Criteria for Adverse Events; RT, radiotherapy.
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the ANN model predicts grade 2-3 nocturia, including
bladder volume, prescribed dose, margins between clinical
target volume (CTV) and planning target volume (PTV),
and dose volume histogram (DVH) information to be sig-
nificant technical-dosimetric factors.
It is evident that to clarify this issue, new trials
focused on clinical as well as dosimetric factors affecting
the GU syndrome should be specifically designed, thus
facilitating the construction of predictive tools to better
tailor treatments to the individual patient.
Bowel Complications
Acute and late radiation enteropathy is an issue when
prostate cancer radiotherapy involves lymph node irradia-
tion. The existence of a large dose-volume effect for bowel
is well assessed from clinical evidence,18,19 and quantita-
tive dose-volume relationships for this endpoint are dis-
cussed elsewhere in this supplement. When considering
clinical risk factors, an investigation recently conducted at
the San Raffaele Institute (on a population of 191
patients) showed a correlation between acute bowel toxic-
ity and previous abdominal surgery20 (odds ratio ¼ 2.4;
P ¼ .05). This point is in agreement with Huang et al,21
who found a higher risk in gynecological patients previ-
ously submitted to abdominal surgery.
These points constitute only initial knowledge of
the factors affecting bowel morbidity, and further studies
are needed to develop predictive tools that might help in
minimizing the insurgence of radiation enteropathy.
Erectile Dysfunction
As well as bowel and GU morbidities, factors influencing
the occurrence of postradiation erectile dysfunction have
not yet been adequately studied and understood. No stud-
ies performed to date in prostate cancer patients under-
going radiation have thoroughly analyzed the possible
influence of patients’ previous medical history, comorbid-
ities, and related drug consumption and tumor stage, or
attempted to discriminate the influence of the disease or
of psychologic burden in estimating the risk of erectile
dysfunction in patients undergoing watchful waiting or
active surveillance. This issue is further complicated by
the lack of evidence-based knowledge of the anatomical
regions involved in the expression of erectile dysfunction.
If several clues point to the penile bulb as the true target
for radio-induced erectile dysfunction, other anatomic
regions that appear to to play a major role in achieving an
erection have also been considered, such as the neurovas-
cular bundles, the crura, and the corpora cavernosa.
A very interesting point comes from recent data on
genes predicting erectile dysfunction. Peters et al22 found
that the possession of certain transforming growth
factorb1 genotypes is associated with the development of
erectile dysfunction. Therefore, the individuation of
patients harboring these genotypes may represent a means
of identifying men who could have poor quality of life af-
ter EBRT for prostate cancer.
Rectal Complications
The role of dosimetric variables influencing rectal toxicity
appears to be quite well understood. A solid set of dose
volume constraints (V40Gy ! V75Gy) and logistic
curves estimating the risk of rectal injury associated with
these constraints are readily available in the literature and
routinely used in clinical practice.14,23-28 More sophisti-
cated tools are also accessible, such as those that reduce all
DVH information to the Equivalent Uniform Dose and
those using normal tissue complication probability
(NTCP) models.29-31 A detailed discussion of dosimetric
predictors of the rectal syndrome is provided elsewhere in
this supplement.
In dealing with the role of clinical variables, a more
complex scenario appears. Recent studies on large, pro-
spectively followed populations have established clear
evidence of the negative impact on late rectal side effects
of both abdominal surgery before EBRT14,27 and acute
LGI toxicity,14,15,32 as well as the protective effect of hor-
monal treatment (because of prostate downsizing) on
acute LGI toxicity.14,33 However, several clinical factors
still need to be fully understood: no consensus exists on
the true influence of diabetes and related drugs,27 of
hypertension and related drugs, of the concomitant use
of anticoagulants and antiaggregants, on the role of
androgen deprivation,32,34-36 or on the exact impact of
hemorrhoids on late rectal morbidity. Table 2 summa-
rizes the major findings (on late rectal bleeding) from
selected studies.
Last but not least, the possible influence on toxicity
of individual genetic susceptibility to radiation is still in
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the ‘‘Stone Age’’ and should be elucidated because, given
the same set of clinical/dosimetric factors, patient-to-
patient variability in normal tissue response to radiation
has been widely recognized in clinical practice, suggesting
that this phenomenon might be, at least in part, geneti-
cally driven.
Predictive Models Integrating Clinical and
Dosimetric Information
There is only 1 paper published to date in which a user-
friendly, clinical/dosimetric predictive radiotoxicity tool
(estimating the risk of acute LGI side effects after confor-
mal irradiation for prostate cancer) was used.37 In this ar-
ticle, a set of nomograms were proposed as instruments to
estimate the risk of acute rectal toxicity. Four endpoints
were considered: 1) G2-G3 RTOG/EORTC LGI toxicity
(Fig. 1), 2) moderate/severe rectal bleeding (Fig. 2), 3)
severe fecal incontinence (Fig. 3), and 4) moderate/severe
increased stool frequency (Fig. 4). All nomograms were
developed on the basis of a large database (1132 patients)
derived from the Italian multicenter AIROPROS 0102
trial.27,33 It was specifically focused on trying to elucidate
potential variables affecting the radio-induced rectal syn-
drome using a prospective evaluation of both RTOG/
EORTC LGI morbidity and a self-reported questionnaire
analyzing several symptoms of the rectal syndrome. These
nomograms, even if not yet validated on independent sets
of patients, constitute an initial tool with which to assess
the single-patient probability of exhibiting acute LGI
morbidity. It is worth remembering that late GI toxicity
has been widely recognized as 1 of the most important
radiation-induced morbidities, as it presents in a signifi-
cant proportion of irradiated prostate cancer patients and
may persist for several years after the completion of radio-
therapy. Nonetheless, moderate/severe acute gastrointesti-
nal side effects, even if typically transient in nature, can
occur in approximately 25% of patients (25.9% in our
Table 2. Clinical Factors Found to Be Correlated With Late Rectal Bleeding (Organ: Rectum;








Feigenberg 200535 1204 Androgen deprivation >6 mo vs 6 mo 1.3 <.01 Modified Fox Chase grade 2
Sanguineti 200234 182 Androgen deprivation Yes vs no 2.2 .02 RTOG grade 2
Vargas 200532 331 Acute lower GI toxicity Yes vs no 2.1 .005 RTOG grade 2
Peeters 200514 553 Acute proctitis Yes vs no 1.5 .01 Intermittent bleeding
Peeters 200514 553 Acute mucous discharge Yes vs no 1.6 .001 Intermittent bleeding
Zelefsky 200815 1571 Acute toxicity Grade 2 vs grade <2 6.95 <.01 Late GI toxicity, CTCAE grade 2
Cahlon 200816 478 Acute lower GI toxicity Grade 2 vs grade <2 <.01 Late GI toxicity, CTCAE grade 2
Peeters 200514 641 Abdominal surgery Yes vs no 2.7 <.01 Bleeding requiring laser or transfusion
Fiorino 200827 506 Abdominal surgery Yes vs no 4.4 .06 Bleeding requiring laser or
transfusion more than twice weekly
RTOG indicates Radiation Therapy Oncology Group; GI, gastrointestinal; CTCAE, Common Terminology Criteria for Adverse Events.
FIGURE 1. A nomogram for moderate/severe Radiation Ther-
apy Oncology Group/European Organization for Research
and Treatment of Cancer (RTOG/EORTC) lower gastrointesti-
nal acute toxicity is shown. G2/G3 indicates grade 2/grade 3;
Gy, grays; Prob., probability. Reprinted from Valdagni R, Ran-
cati T, Fiorino C, et al. Development of a set of nomograms
to predict acute lower gastrointestinal toxicity for prostate
cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008;71:1065-
1073, with permission from Elsevier.
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experience33), and there is mounting evidence that acute
damage plays a significant role in late toxicity.14,32 Conse-
quently, the highly probable prediction of acute toxicity
could avoid unnecessary daily costs for the individual
patient in terms of quality of life modification during
treatment and possibly afterward, and could help clini-
cians in better tailoring the treatment to patient
characteristics.
With respect to late toxicity, to date, only 1 model
exploiting ANNs has been published to date.17 This
ANN model helps to predict G2-G3 late rectal bleeding
and includes rectal volume, prescribed dose, margins
between CTV and PTV, and DVH information as signifi-
cant technical-dosimetric factors.
With respect to nomogram prediction of late LGI
toxicity, no published data are yet available. Data from
615 patients of the AIROPROS 0102 trial with a mini-
mum follow-up of 36 months are now becoming avail-
able, and a set of nomograms predicting late morbidity
will be the object of a future publication. Figure 5 shows
the first of these nomograms, which predicts the risk of
G2-G3 late rectal bleeding. In multivariate logistic analy-
sis, V75Gy was found to be significantly correlated with
G2-G3 late rectal bleeding, together with abdominal
FIGURE 2. A nomogram for moderate/severe acute rectal
bleeding is shown. Gy indicates grays; Prob., probability.
Reprinted from Valdagni R, Rancati T, Fiorino C, et al. Devel-
opment of a set of nomograms to predict acute lower gastro-
intestinal toxicity for prostate cancer 3D-CRT. Int J Radiat
Oncol Biol Phys. 2008;71:1065-1073, with permission from
Elsevier.
FIGURE 3. A nomogram for severe acute fecal incontinence
is shown. Gy indicates grays; Prob., probability. Reprinted
from Valdagni R, Rancati T, Fiorino C, et al. Development of a
set of nomograms to predict acute lower gastrointestinal tox-
icity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys.
2008;71:1065-1073, with permission from Elsevier.
FIGURE 4. A nomogram for moderate/severe acute increased
bowel frequency is shown. Gy indicates grays; Prob., proba-
bility. Reprinted from Valdagni R, Rancati T, Fiorino C, et al.
Development of a set of nomograms to predict acute lower
gastrointestinal toxicity for prostate cancer 3D-CRT. Int J
Radiat Oncol Biol Phys. 2008;71:1065-1073, with permission
from Elsevier.
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surgery before conformal irradiation and the presence of
G2-G3 acute LGI toxicity. To develop a pretreatment
nomogram estimating G2-G3 late rectal bleeding and
considering the significant correlation between acute and
late LGI morbidity, the nomogram predicting acute LGI
G2-G3 RTOG/EORTC acute toxicity (Fig. 1) was
included in the nomogram predicting G2-G3 late rectal
bleeding. With this substitution, V75Gy together with
abdominal surgery before EBRT and predicted acute LGI
toxicity (dichotomized variable: cutoff value ¼ 32%) are
used for the single patient evaluation of late rectal bleed-
ing probability.
Predictive Models Integrating
Clinicodosimetric and Genetic Information
Current radiotherapy practice is based on the assumption
that the human population is uniform in its radiation sen-
sitivity, with limited and dramatic exceptions being well
recognized (ataxia telangiectasia, Fanconi anemia, Nijme-
gen breakage syndrome). However, there are several
indications from human studies suggesting that this
assumption regarding uniform radiosensitivity is incor-
rect. It is also evident that, despite the utilization of highly
sophisticated technology and the strict application of dose
constraints, 3% to 10% of our patients still show evidence
of moderate/severe rectal injury. Very few studies in the
literature attempt to identify biological predictors of
acute/late toxicity in prostate cancer irradiation, or exam-
ine the potential correlation between rectal injury, dosi-
metric variables, clinical factors, and the individual gene
profile in the single patient. Data on genes influencing
late rectal bleeding have recently become available,38-41
but knowledge of the impact of gene expression profiling
on radiotoxicity remains at a very primitive stage. To date,
there exists no predictive tool that includes genetic infor-
mation. Nonetheless, it is highly reasonable to expect
that, in the near future, nomograms incorporating the
genetic makeup of the single patient may become clini-
cally relevant for the better individualization of radiation
treatment for the individual patient. Figure 6 shows such
a hypothetical nomogram, derived from AIROPROS
0102 data27,33 and predicting late rectal bleeding. The
inclusion of LSM7 expression (the real weight on toxicity
predictions is unknown) was made on the basis of the
recent results of a pilot study39 that identifies several genes
potentially predictive for rectal toxicity. In the near future,
genetic composition may be routinely combined with
dosimetric and clinical variables to fully assess patient risk
FIGURE 5. A nomogram for grade 2 to 3 late rectal bleeding
is shown. G2-G3 indicates grade 2-3; LGI, lower gastrointesti-
nal; Gy, grays; Prob., probability.
FIGURE 6. A hypothetical nomogram for the prediction of
late rectal bleeding is shown, with inclusion of the single-
patient LSM7 expression for radiosensitivity. G2-G3 indicates
grade 2-3; LGI, lower gastrointestinal; Gy, grays; Prob.,
probability.
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of radio-induced toxicity, and nomograms may thus
include genetic as well as dosimetric and clinical
information.
DISCUSSION
In the last decade, several investigators in the field of pros-
tate cancer irradiation have developed and applied ‘‘indi-
vidualized’’ predictive tools (such as probability formulas
and nomograms), as well as ‘‘nonindividualized’’ tools
(such as risk classes), to estimate the risk of disease failure/
control in its various clinical endpoints or surrogates, to
better select targets for external radiation, to decide radia-
tion dose, and lastly, to suggest the optimal combination
therapy (eg, androgen deprivation).
Nonetheless, the study of predictors of radio-
induced morbidity has been relegated essentially to an
evaluation of the role of dosimetric variables, with the
integration of clinical variables in predictive models only
recently gaining the attention of the radiation commu-
nity. When organs at risk of developing radiation sequelae
are considered, an analysis of the literature reveals that
most efforts to elucidate the influence of toxicity factors
have been oriented toward analyzing variables that esti-
mate the risk of rectal morbidity, with information on
bladder, urethra, bowel, and anatomic regions causing
erectile dysfunction being very scarce or limited to dosi-
metric data only.
Several reports using uni-/multivariate (logistic/
actuarial) analysis are available for an estimate of the risk
of gastrointestinal (and to a very minor extent, GU) com-
plications. Studies regarding radio-induced rectal morbid-
ity, although providing a solid set of dose-volume
constraints to be observed to keep the probability of such
morbidity reasonably low, do not definitively clarify the
role of some clinical variables (such as the presence of dia-
betes or hypertension, or the use of concomitant androgen
deprivation). For this reason, the predictive accuracy of
these models may be limited, because in general they rely
heavily on dosimetric variables, whereas other important
factors (eg, comorbidities, concomitant use of drugs) are
either not globally taken into account, or not yet under-
stood (eg, genetic variables). Only recently, 2 large pro-
spective investigations (the Dutch trial14 and the Italian
trial AIROPROS 010227,33) were conducted with the spe-
cific goal of analyzing the correlation between clinical and
dosimetric variables and the symptoms of the so-called
rectal syndrome. Data derived from AIROPROS 0102
incorporating dosimetric as well as clinical information
have allowed the development of the first set of nomo-
grams predicting several symptoms of the acute rectal syn-
drome37 and the first nomogram regarding late rectal
bleeding. Other nomograms estimating the risk of several
clinical events of late rectal toxicity in the individual
patient are in the process of being developed.42
It must be emphasized that only preliminary data
exist on the potential influence of individual genetic sus-
ceptibility to radiation injury,38-41 but interpatient vari-
ability in normal tissue response to radiation suggests that
in the near future, the genetic makeup of the individual
patient will be incorporated in predictive modeling.
Conclusions
Predicting a high probability of toxicity could avoid
unnecessary daily costs to the single patient in terms of
quality of life modification during and after treatment,
helping patients in the decision-making process, and clini-
cians in better tailoring the treatment to patient character-
istics. Specifically, radiation oncologists might consider
modifying: 1) treatment planning, introducing more
stringent DVH constraints to have a reasonably lower risk
of the specific endpoint considered; and/or 2) the treat-
ment technique, shifting for example from 3DCRT to
IMRT or image-guided radiation therapy; and/or 3) the
radiation strategy (eg, adding, in selected cases, hormonal
therapy to a lower prescription dose). Lastly, it could facil-
itate clinicians in counseling and directing the patient
with regard to alternative treatment modalities, namely
radical prostatectomy, high-intensity focused ultrasound,
or cryotherapy.
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